FindTrial
Sign In

Evaluation of 18F-FDG-PET/CT in the diagnosis and treatment response of bone metastasis.

Evaluation of 18F-FDG-PET/CT in the diagnosis and treatment response of bone metastasis. - 18F-FDG-PET/CT in bone metastasis.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-UMIN000005866
Enrollment
220
Registered
2011-06-28
Start date
2011-06-28
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bone metastasis

Interventions

None listed

Sponsors

National Cancer Center Research Projects Management expenses Grants from the Government to National Cancer Research Center
Lead Sponsor
Shikoku Cancer Center, Yokohama City University, Shizuoka Cancer Center, Kanazawa University Hospital, National Cancer Center Hospital, Cancer Institute Hospital
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients with bone metastasis

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

MeasureTime frame
The Diagnostic rate of PET/CT for bone metastasis is compared with that of bone scintigraphy. The utility of PET/CT in determining the treatment response of bone metastasis is evaluated.—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026